HIV-1 Latency: an Update of Molecular Mechanisms and Therapeutic Strategies

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2014 Apr 17

PMID 24736215

Citations 39

Authors

Angela Battistini

Marco Sgarbanti

Affiliations

Soon will be listed here.

Abstract

The major obstacle towards HIV-1 eradication is the life-long persistence of the virus in reservoirs of latently infected cells. In these cells the proviral DNA is integrated in the host's genome but it does not actively replicate, becoming invisible to the host immune system and unaffected by existing antiviral drugs. Rebound of viremia and recovery of systemic infection that follows interruption of therapy, necessitates life-long treatments with problems of compliance, toxicity, and untenable costs, especially in developing countries where the infection hits worst. Extensive research efforts have led to the proposal and preliminary testing of several anti-latency compounds, however, overall, eradication strategies have had, so far, limited clinical success while posing several risks for patients. This review will briefly summarize the more recent advances in the elucidation of mechanisms that regulates the establishment/maintenance of latency and therapeutic strategies currently under evaluation in order to eradicate HIV persistence.

Citing Articles

Friends and Foes: The Ambivalent Role of Autophagy in HIV-1 Infection.

Klute S, Sparrer K Viruses. 2024; 16(4).

PMID: 38675843 PMC: 11054699. DOI: 10.3390/v16040500.

scPathoQuant: a tool for efficient alignment and quantification of pathogen sequence reads from 10× single cell sequencing datasets.

Whitmore L, Tisoncik-Go J, Gale Jr M Bioinformatics. 2024; 40(4).

PMID: 38478395 PMC: 10990681. DOI: 10.1093/bioinformatics/btae145.

Biological Properties of Latex, Aqueous Extracts and Bee Products of L.: A Short Review.

Boutoub O, El Ghadraoui L, Miguel M Molecules. 2022; 27(21).

PMID: 36364025 PMC: 9656204. DOI: 10.3390/molecules27217200.

HIV cure strategies: which ones are appropriate for Africa?.

Abana C, Lamptey H, Bonney E, Kyei G Cell Mol Life Sci. 2022; 79(8):400.

PMID: 35794316 PMC: 9259540. DOI: 10.1007/s00018-022-04421-z.

Fighting HIV-1 Persistence: At the Crossroads of "Shoc-K and B-Lock".

Acchioni C, Palermo E, Sandini S, Acchioni M, Hiscott J, Sgarbanti M Pathogens. 2021; 10(11).

PMID: 34832672 PMC: 8622007. DOI: 10.3390/pathogens10111517.

References

Brenchley J, Price D, Schacker T, Asher T, Silvestri G, Rao S . Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006; 12(12):1365-71. DOI: 10.1038/nm1511. View

van Praag R, Prins J, Roos M, Schellekens P, ten Berge I, Yong S . OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion. J Clin Immunol. 2001; 21(3):218-26. DOI: 10.1023/a:1011091300321. View

Sereti I, Imamichi H, Natarajan V, Imamichi T, Ramchandani M, Badralmaa Y . In vivo expansion of CD4CD45RO-CD25 T cells expressing foxP3 in IL-2-treated HIV-infected patients. J Clin Invest. 2005; 115(7):1839-47. PMC: 1142113. DOI: 10.1172/JCI24307. View

Tebas P, Stein D, Tang W, Frank I, Wang S, Lee G . Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med. 2014; 370(10):901-10. PMC: 4084652. DOI: 10.1056/NEJMoa1300662. View

Taube R, Peterlin M . Lost in transcription: molecular mechanisms that control HIV latency. Viruses. 2013; 5(3):902-27. PMC: 3705304. DOI: 10.3390/v5030902. View

Banerjee C, Archin N, Michaels D, Belkina A, Denis G, Bradner J . BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J Leukoc Biol. 2012; 92(6):1147-54. PMC: 3501896. DOI: 10.1189/jlb.0312165. View

Emery S, Capra W, Cooper D, Mitsuyasu R, Kovacs J, Vig P . Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease. J Infect Dis. 2000; 182(2):428-34. DOI: 10.1086/315736. View

He G, Margolis D . Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator Tat. Mol Cell Biol. 2002; 22(9):2965-73. PMC: 133763. DOI: 10.1128/MCB.22.9.2965-2973.2002. View

Shan L, Yang H, Rabi S, Bravo H, Shroff N, Irizarry R . Influence of host gene transcription level and orientation on HIV-1 latency in a primary-cell model. J Virol. 2011; 85(11):5384-93. PMC: 3094997. DOI: 10.1128/JVI.02536-10. View

10.

Marban C, Suzanne S, Dequiedt F, de Walque S, Redel L, Van Lint C . Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing. EMBO J. 2007; 26(2):412-23. PMC: 1783449. DOI: 10.1038/sj.emboj.7601516. View

11.

Ruff V, Leach K . Direct demonstration of NFATp dephosphorylation and nuclear localization in activated HT-2 cells using a specific NFATp polyclonal antibody. J Biol Chem. 1995; 270(38):22602-7. DOI: 10.1074/jbc.270.38.22602. View

12.

Doyon G, Zerbato J, Mellors J, Sluis-Cremer N . Disulfiram reactivates latent HIV-1 expression through depletion of the phosphatase and tensin homolog. AIDS. 2012; 27(2):F7-F11. DOI: 10.1097/QAD.0b013e3283570620. View

13.

Jern P, Coffin J . Effects of retroviruses on host genome function. Annu Rev Genet. 2008; 42:709-32. DOI: 10.1146/annurev.genet.42.110807.091501. View

14.

Popovic M, Sarngadharan M, Read E, Gallo R . Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science. 1984; 224(4648):497-500. DOI: 10.1126/science.6200935. View

15.

Said E, Dupuy F, Trautmann L, Zhang Y, Shi Y, El-Far M . Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection. Nat Med. 2010; 16(4):452-9. PMC: 4229134. DOI: 10.1038/nm.2106. View

16.

Shirakawa K, Chavez L, Hakre S, Calvanese V, Verdin E . Reactivation of latent HIV by histone deacetylase inhibitors. Trends Microbiol. 2013; 21(6):277-85. PMC: 3685471. DOI: 10.1016/j.tim.2013.02.005. View

17.

Levy Y, Sereti I, Tambussi G, Routy J, Lelievre J, Delfraissy J . Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study. Clin Infect Dis. 2012; 55(2):291-300. PMC: 3381639. DOI: 10.1093/cid/cis383. View

18.

Crowe S, Zhu T, Muller W . The contribution of monocyte infection and trafficking to viral persistence, and maintenance of the viral reservoir in HIV infection. J Leukoc Biol. 2003; 74(5):635-41. DOI: 10.1189/jlb.0503204. View

19.

Hammer S, Squires K, Hughes M, Grimes J, Demeter L, Currier J . A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997; 337(11):725-33. DOI: 10.1056/NEJM199709113371101. View

20.

Routy J, Tremblay C, Angel J, Trottier B, Rouleau D, Baril J . Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study. HIV Med. 2012; 13(5):291-6. DOI: 10.1111/j.1468-1293.2011.00975.x. View